There are quite a few good reasons for buying Novo Nordisk (NYSE: NVO) stock. Between its hit type 2 diabetes drug Ozempic (raking in sales so fast that the company can't produce it fast enough) and its drug development pipeline that's packed with additional opportunities for growth, it's no surprise why its shares are up 82% in the last 12 months.

But, like all hot stocks, there are plenty of bad arguments about why it's worth buying or selling. Let's analyze three of the most common lackluster arguments for why you should avoid or sell this stock so that you'll get a better sense of which factors actually matter and why.

One weak reason to avoid Novo Nordisk stock is that it's at the height of the Ozempic hype cycle at the moment. People who buy it now will thus be missing out on the upside of the run-up, yet still exposed to the (inevitable, in the view of critics) collapse when Ozempic sales eventually fade. But this argument misses the fact that Ozempic's reign has barely just begun.

Continue reading

Source Fool.com